Definition of pharmacodynamic biomarkers for juvenile dermatomyositis for clinical trials

Project: Research project

Project Details

StatusFinished
Effective start/end date6/5/18 → 11/30/19

Funding

  • Reveragen Biopharma, Inc. (1R43AR073547-01)
  • National Institutes of Health (1R43AR073547-01)